Cargando…

Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study

AIM: Globally, evidence from short‐term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long‐term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishigooka, Jun, Nakagome, Kazuyuki, Ohmori, Tetsuro, Iwata, Nakao, Inada, Ken, Iga, Jun‐ichi, Kishi, Taro, Fujita, Kiyoshi, Kikuchi, Yuka, Shichijo, Toshiaki, Tabuse, Hideaki, Koretsune, Shotatsu, Terada, Hiroshi, Terada, Haruko, Kishimoto, Toshifumi, Tsutsumi, Yuichiro, Kanda, Yoshiki, Ohi, Kazutaka, Sekiyama, Kanji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299006/
https://www.ncbi.nlm.nih.gov/pubmed/34626144
http://dx.doi.org/10.1111/pcn.13304
_version_ 1784750845226647552
author Ishigooka, Jun
Nakagome, Kazuyuki
Ohmori, Tetsuro
Iwata, Nakao
Inada, Ken
Iga, Jun‐ichi
Kishi, Taro
Fujita, Kiyoshi
Kikuchi, Yuka
Shichijo, Toshiaki
Tabuse, Hideaki
Koretsune, Shotatsu
Terada, Hiroshi
Terada, Haruko
Kishimoto, Toshifumi
Tsutsumi, Yuichiro
Kanda, Yoshiki
Ohi, Kazutaka
Sekiyama, Kanji
author_facet Ishigooka, Jun
Nakagome, Kazuyuki
Ohmori, Tetsuro
Iwata, Nakao
Inada, Ken
Iga, Jun‐ichi
Kishi, Taro
Fujita, Kiyoshi
Kikuchi, Yuka
Shichijo, Toshiaki
Tabuse, Hideaki
Koretsune, Shotatsu
Terada, Hiroshi
Terada, Haruko
Kishimoto, Toshifumi
Tsutsumi, Yuichiro
Kanda, Yoshiki
Ohi, Kazutaka
Sekiyama, Kanji
author_sort Ishigooka, Jun
collection PubMed
description AIM: Globally, evidence from short‐term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long‐term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large‐scale, long‐term naturalistic study to present pivotal 52‐week data on the continuity of second‐generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). METHODS: JUMPs was an open‐label, three‐arm, randomized, parallel‐group, 52‐week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality‐of‐life scores [Personal and Social Performance Scale (PSP) and EuroQol‐5 dimensions], and safety. RESULTS: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. CONCLUSION: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan.
format Online
Article
Text
id pubmed-9299006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-92990062022-07-21 Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study Ishigooka, Jun Nakagome, Kazuyuki Ohmori, Tetsuro Iwata, Nakao Inada, Ken Iga, Jun‐ichi Kishi, Taro Fujita, Kiyoshi Kikuchi, Yuka Shichijo, Toshiaki Tabuse, Hideaki Koretsune, Shotatsu Terada, Hiroshi Terada, Haruko Kishimoto, Toshifumi Tsutsumi, Yuichiro Kanda, Yoshiki Ohi, Kazutaka Sekiyama, Kanji Psychiatry Clin Neurosci Regular Article AIM: Globally, evidence from short‐term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long‐term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large‐scale, long‐term naturalistic study to present pivotal 52‐week data on the continuity of second‐generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). METHODS: JUMPs was an open‐label, three‐arm, randomized, parallel‐group, 52‐week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality‐of‐life scores [Personal and Social Performance Scale (PSP) and EuroQol‐5 dimensions], and safety. RESULTS: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. CONCLUSION: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan. John Wiley & Sons Australia, Ltd 2021-11-17 2022-01 /pmc/articles/PMC9299006/ /pubmed/34626144 http://dx.doi.org/10.1111/pcn.13304 Text en © 2021 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Regular Article
Ishigooka, Jun
Nakagome, Kazuyuki
Ohmori, Tetsuro
Iwata, Nakao
Inada, Ken
Iga, Jun‐ichi
Kishi, Taro
Fujita, Kiyoshi
Kikuchi, Yuka
Shichijo, Toshiaki
Tabuse, Hideaki
Koretsune, Shotatsu
Terada, Hiroshi
Terada, Haruko
Kishimoto, Toshifumi
Tsutsumi, Yuichiro
Kanda, Yoshiki
Ohi, Kazutaka
Sekiyama, Kanji
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
title Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
title_full Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
title_fullStr Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
title_full_unstemmed Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
title_short Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
title_sort discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of jumps, a randomized, open‐label study
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299006/
https://www.ncbi.nlm.nih.gov/pubmed/34626144
http://dx.doi.org/10.1111/pcn.13304
work_keys_str_mv AT ishigookajun discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT nakagomekazuyuki discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT ohmoritetsuro discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT iwatanakao discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT inadaken discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT igajunichi discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT kishitaro discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT fujitakiyoshi discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT kikuchiyuka discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT shichijotoshiaki discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT tabusehideaki discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT koretsuneshotatsu discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT teradahiroshi discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT teradaharuko discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT kishimototoshifumi discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT tsutsumiyuichiro discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT kandayoshiki discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT ohikazutaka discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy
AT sekiyamakanji discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy